FTC Accuses Martin Shkreli of Violating Lifetime Pharma Ban

Martin Shkreli, the former pharmaceutical executive whose name became synonymous with drug-pricing controversy, is now facing contempt proceedings brought by the Federal Trade Commission and a coalition of state attorneys general. Regulators allege he violated the terms of a lifetime ban that barred him from participating in the pharmaceutical industry — a sweeping prohibition imposed after courts found he had orchestrated an illegal monopoly scheme.

The ban itself stemmed from a landmark antitrust case centered on Daraprim, a decades-old antiparasitic drug used by vulnerable patients including those with HIV. A trial concluded that Shkreli engineered a scheme designed to lock out generic competition and preserve his company's exclusive grip on the market — conduct that regulators and judges found egregious enough to warrant permanent exclusion from the industry.

Read more Republican Senators Push Back on Trump's Diesel Deal With Putin →

Contempt charges in civil cases carry real consequences: courts can impose fines, sanctions, or additional restrictions on defendants found to have willfully defied prior orders. The FTC's willingness to pursue this action alongside state partners signals that regulators view the alleged violations as serious and deliberate, not technical or inadvertent.

The case is a reminder that even after landmark enforcement actions conclude, the work of ensuring compliance with court orders is an ongoing and resource-intensive challenge for regulators. For Shkreli, who has maintained a public profile since his earlier legal troubles, the contempt claim represents a significant new legal jeopardy built directly on top of prior judgments against him.

Continue reading at US Top News and Analysis